Spotlight On... Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections; Oral wet AMD player raises $12M; Novel hep B candidate funded to tune of $3M; and more...

Israel's PolyPid just raised $22 million from new investor Shavit Capital and others in a bid to put its lead surgical drug reservoir candidate into Phase III. The candidate releases the antibiotic doxycycline hyclate over four weeks, and is intended for patients suffering from severe open tibia fractures who are at high risk of infection. More

> Tyrogenex has raised $12 million in support of its oral therapy for the eye condition wet AMD. More

> Chromis Therapeutics has raised $3 million in support of its Hep B candidate that targets covalently closed circular DNA. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.